Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 88Active not recruiting 48Completed 21Not yet recruiting 8Terminated 6Enrolling by invitation 5Suspended 1Available 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 43Other hematologic neoplasm 28CNS 24Lymphoid 23Genitourinary 23Breast 22Thoracic 20Head & Neck 14Tumor-Agnostic 12Other solid neoplasm 12Gynecologic 12Sarcoma 10Myeloid 9Plasma cell 7Dermatologic 7Other 3Endocrine 3Classical hematology 3Other neoplasm 1NET 1

Conditions

Vulvar Neoplasms 1Sarcoma 1Prostatic Neoplasms 1Ovarian Neoplasms 1Neuroendocrine Tumors 1Gallbladder Neoplasms 1Carcinoma, Neuroendocrine 1Breast Neoplasms 1Bile Duct Neoplasms 1

Interventions

tivozanib 1atezolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × NET × 1 year × Clear all
NCT05000294 2026-02-18

Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types

University of Florida

Phase 1/2 Suspended
29 enrolled
BreastEndocrineGastrointestinalGenitourinaryGynecologicNETSarcoma

Bile Duct Neoplasms, Breast Neoplasms, Gallbladder Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Sarcoma, Vulvar Neoplasms, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡